SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is capturing significant attention as investors react to a new strategic partnership with Nvidia, designed to deliver secure AI solutions for critical infrastructure and government agencies. Community sentiment is deeply divided, featuring intense debates between bulls betting on massive free cash flow growth and bears who argue the stock remains overvalued and susceptible to volatility.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster Inc. is trending as investors react to the company's newly announced manufacturing expansion with Benchmark Electronics, which aims to scale production of its Rev8 lidar sensors to meet rising demand in robotics and physical AI applications. Community sentiment remains overwhelmingly bullish, with active discussions focusing on the company's BABA-compliant technology, strategic growth in the smart infrastructure sector, and its pivot toward becoming a foundational perception platform for autonomous systems.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is generating significant community interest as investors weigh its aggressive expansion into telecommunications and energy markets against a high short interest, which continues to fuel intense debate over a potential short squeeze. Traders are closely monitoring technical support levels and upcoming earnings, with active discussions focusing on the company's patent portfolio and its ability to turn enterprise partnerships into sustained revenue growth.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending due to heightened community interest in its potential for a short squeeze, driven by significant short interest and optimism surrounding its international expansion and Alani Nu growth. Investors are actively debating the company's long-term valuation compared to sector competitors, with many looking toward an upcoming earnings catalyst to break the stock out of its recent consolidation.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors anticipate upcoming global expansion news and potential catalysts in July, with community members actively discussing the company's NK cell platform and its potential to disrupt traditional cancer treatments. Bullish sentiment is heavily fueled by high short interest and anticipation of a potential squeeze, as supporters rally around the company's progress in clinical trials and manufacturing infrastructure.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to the initiation of the global Phase 3 AURORA trial for NSCLC and the appointment of a veteran industry executive as Chief Commercial Officer, signaling a significant push toward commercialization. The community is actively debating the company's valuation potential against recent progress in its pipeline, with sentiment divided between enthusiasm for its late-stage oncology programs and concerns over potential dilution or historical leadership performance.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is experiencing significant downward pressure following reports that Meta Platforms may commercialize excess AI compute, sparking investor concerns over potential oversupply and increased competition for the neocloud sector. While the community remains divided between those viewing the pullback as a narrative-driven overreaction to a long-term infrastructure trend and those concerned about the erosion of competitive moats for smaller providers, sentiment remains heavily focused on the company's existing multi-year capacity contracts and the broader, supply-constrained nature of AI compute.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is trending as retail investors rally behind a potential short-squeeze setup, highlighting its small float, high short interest, and low market valuation. Community members are actively debating the mechanics of a squeeze, frequently drawing comparisons to other recent fast-food-sector movers and historical meme-stock surges.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing strong bullish momentum driven by a recent Wedbush initiation with a significant upside price target and the company's strategic positioning at the intersection of defense and quantum technology following recent White House executive orders. The community is actively discussing a potential short squeeze and the company's unique role as a neutral-atom hardware leader, with many retail investors expressing high conviction in its long-term growth as it secures major government backing.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as traders react to a wave of bullish analyst initiations, including a new Buy rating from BTIG, while ongoing product expansion into prediction markets, crypto, and international banking drives significant social media volume and investor optimism regarding long-term growth. The stock remains a high-beta focal point as the community debates whether upcoming events and unique offerings like 'Trump Accounts' will serve as a catalyst for sustained momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Key PointsADAR1 Capital Management added 829,963 shares of Crinetics Pharmaceuticals; estimated trade size $37.07 million based on quarterly average pricing...

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -0.82% and +42.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jennison Associates LLC Sells 763,133 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Jennison Associates LLC reduced its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 37.3% in the fourth quarter, according to the company in its most recent Form 13F filing...

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pictet Asset Management Holding SA Has $72.63 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX

Pictet Asset Management Holding SA lifted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,560,300 shares of the...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $97.00 Price Target at Citizens Jmp

Citizens Jmp upped their target price on Crinetics Pharmaceuticals from $96.00 to $97.00 and gave the company a "market outperform" rating in a research report on Tuesday...

Impax Asset Management Group plc Buys Shares of 275,000 Crinetics Pharmaceuticals, Inc. $CRNX

Impax Asset Management Group plc bought a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to the company in its most recent...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the...

Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates

Amneal (AMRX) delivered earnings and revenue surprises of +63.64% and +1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$38.68
Prev Close	$37.42
Open	$37.49
Dividend Yield	0.00%
50-Day Moving Average	$36.72
Beta	1.18
Avg. Volume	1.24M
PE Ratio	-7.54

52-Week High	$57.99
52-Week Low	$25.83
Market Capitalization	$3.95B
EPS (Annual)	-$4.95
Price to Book	3.18
Revenue Per Employee	$12,956.23

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRNXCrinetics Pharmaceuticals Inc

Latest CRNX News